Compare IDEXX Laboratories, Inc. (IDXX) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.79. The key difference: Roundhill Innov-100 0DTE Covered Call Strat ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | QDTE | |
|---|---|---|
Market Cap | $46.22B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $766.68 | $36.60 |
52-Week Low | $526.44 | $26.85 |
Enterprise Value | $47.12B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
QDTE trades at $29.835, up 0.62% with a bearish technical signal from moving averages. The ETF faces significant concerns about its distribution strategy, with recent analysis highlighting that its high yield is funded by return of capital rather than actual earnings, leading to persistent NAV erosion. Technical indicators show resistance at $30 with support at $29, while RSI levels suggest mixed momentum signals.
The outlook remains cautious as the fund's structural issues with NAV depletion outweigh the appeal of weekly distributions. Investment opportunity exists only for those understanding the return-of-capital mechanics, while risks include continued underperformance and yield sustainability concerns in changing volatility environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →
